Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

J Natl Cancer Inst 2013 Jun 29;105(11):812-22. Epub 2013 Apr 29.

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Manchester, UK.

Background: Reliable estimates of cancer risk are critical for guiding management of BRCA1 and BRCA2 mutation carriers. The aims of this study were to derive penetrance estimates for breast cancer, ovarian cancer, and contralateral breast cancer in a prospective series of mutation carriers and to assess how these risks are modified by common breast cancer susceptibility alleles.

Methods: Prospective cancer risks were estimated using a cohort of 978 BRCA1 and 909 BRCA2 carriers from the United Kingdom. Nine hundred eighty-eight women had no breast or ovarian cancer diagnosis at baseline, 1509 women were unaffected by ovarian cancer, and 651 had been diagnosed with unilateral breast cancer. Cumulative risks were obtained using Kaplan-Meier estimates. Associations between cancer risk and covariables of interest were evaluated using Cox regression. All statistical tests were two-sided.

Results: The average cumulative risks by age 70 years for BRCA1 carriers were estimated to be 60% (95% confidence interval [CI] = 44% to 75%) for breast cancer, 59% (95% CI = 43% to 76%) for ovarian cancer, and 83% (95% CI = 69% to 94%) for contralateral breast cancer. For BRCA2 carriers, the corresponding risks were 55% (95% CI = 41% to 70%) for breast cancer, 16.5% (95% CI = 7.5% to 34%) for ovarian cancer, and 62% (95% CI = 44% to 79.5%) for contralateral breast cancer. BRCA2 carriers in the highest tertile of risk, defined by the joint genotype distribution of seven single nucleotide polymorphisms associated with breast cancer risk, were at statistically significantly higher risk of developing breast cancer than those in the lowest tertile (hazard ratio = 4.1, 95% CI = 1.2 to 14.5; P = .02).

Conclusions: Prospective risk estimates confirm that BRCA1 and BRCA2 carriers are at high risk of developing breast, ovarian, and contralateral breast cancer. Our results confirm findings from retrospective studies that common breast cancer susceptibility alleles in combination are predictive of breast cancer risk for BRCA2 carriers.

Download full-text PDF

Source
https://academic.oup.com/jnci/article/105/11/812/1004115
Publisher Site
http://dx.doi.org/10.1093/jnci/djt095DOI Listing
June 2013
104 Reads

Publication Analysis

Top Keywords

breast cancer
52
cancer
22
ovarian cancer
20
brca2 carriers
20
cancer risk
16
contralateral breast
16
breast
15
brca1 brca2
12
mutation carriers
12
carriers
9
developing breast
8
cancer brca2
8
cumulative risks
8
risk developing
8
common breast
8
breast ovarian
8
brca2 mutation
8
cancer susceptibility
8
risk
8
cancer risks
8

References

(Supplied by CrossRef)
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
Easton et al.
Am J Hum Genet 1995

Similar Publications